In Rare Move, FDA Panel Gives Support to Controversial ALS Drug in 2nd Review

THURSDAY, Sept. 8, 2022– In a rare second review, a U.S. Food and Drug Administration panel on Wednesday recommended approval for an experimental drug for ALS (amyotrophic lateral sclerosis). The FDA is not obligated to follow its advisors ' ...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news